TY - JOUR T1 - Decreased risk of treatment failure with vedolizumab and thiopurines combined compared with vedolizumab monotherapy in Crohn's disease JF - Gut JO - Gut SP - 1781 LP - 1789 DO - 10.1136/gutjnl-2022-327002 VL - 71 IS - 9 AU - Julien Kirchgesner AU - Rishi J Desai AU - Maria C Schneeweiss AU - Laurent Beaugerie AU - Sebastian Schneeweiss AU - Seoyoung C Kim Y1 - 2022/09/01 UR - //www.marcconsult.com/content/71/9/1781.abstract N2 - Objective While infliximab combined to thiopurines is more effective than infliximab monotherapy in patients with Crohn's disease (CD) and UC, the impact of adding thiopurines to vedolizumab remains controversial.设计基于二美和二法全域保健数据库, 带CD和UC启动sdolizumab的病人识别研究方法,包括混淆调整和结果定义,先前经SONIC和SUCCESS测试成功模拟验证因住院或外科手术与疾病活动、治疗开关或超时cortcoctiroids使用有关而失效的风险比估计在1:1偏差评分匹配后实现。 Results共10 299vedizumab用户中,804CD和1088UC组合法对vedolizumab单治用户匹配PS26周治疗失败数为236人(29.3%)和376人(34.3%),16周治疗数为236人(21.7%)和263人(24.2%)复用复用法降低治疗失效风险,CD类复用法(RR 0.85,95%CI:0.74至0.98)和UC类复用法(RR 0.90,95%CI:0.77至1.05)。使用验证方法闭合,与vedolizumab和thioprines混合解析与低处理故障相关联不适用ER-